Datroway Gains FDA Nod for First-Line TNBC After Five-Month Survival Gain
AZN•AstraZeneca and Daiichi Sankyo’s Datroway received FDA approval as first-line treatment for adults with unresectable or metastatic triple-negative breast cancer ineligible for PD-1/PD-L1 inhibitors. TROPION-Breast02 trial data showed a five-month overall survival extension versus chemotherapy, 43% reduction in progression risk, and a 64% objective response rate versus 30%.
1. FDA Approval for First-Line TNBC
AstraZeneca and Daiichi Sankyo’s Datroway received FDA clearance for use as a first-line treatment in adults with unresectable or metastatic triple-negative breast cancer who cannot receive PD-1 or PD-L1 inhibitors.
2. TROPION-Breast02 Clinical Results
The Phase III TROPION-Breast02 trial reported a five-month overall survival extension versus chemotherapy, a 43% reduction in disease progression or death risk, and an objective response rate of 64% compared to 30% with standard chemotherapy.
3. Project Orbis Regulatory Collaboration
The application was reviewed under Project Orbis, enabling simultaneous submissions to health authorities in Canada, Australia, Switzerland, and Singapore, with ongoing reviews in Japan, China, and the European Union.
4. Partnership and Next Steps
Datroway, discovered by Daiichi Sankyo and co-developed with AstraZeneca, is under further investigation across additional tumor types, with commercialization preparations and digital pathology collaborations underway to support biomarker discovery.
